Publications
A feasibility study of EMF(erlotinib+methotrexate+5-fluorouracil) regimen in recurrent head and neck squamous cell carcinoma (HNSCC) and role of circulating tumour cells(CTCs) in assessment of outcomes.
Annie Baa, Raja Pramanik, Atul Sharma, Ahitagni Biswas, Sachidanand JeeBharti, Mayank Singh, Rajeev Kumar, Aland Gourishankar, Sreeja Jayant, Alain D'Souza, Vikas Jadhav, and Jayant KhandareAuthors Info & Affiliations Head and neck cancer is a huge burden in South East Asia with frequent relapse after curative therapy while the rest presenting in advanced unresectable stages. Financial constraints for targeted and immunotherapy make it inaccessible for the bulk of population. Thus, low-cost but efficacious regimen is highly implicated. We assessed if readily available triplet therapy of EMF, is superior in terms of extending life and maintaining quality of life along with evaluation of CTCs as a predictive biomarker in such patients.
